KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Treasury Shares: 2012-2024

  • Ionis Pharmaceuticals' Treasury Shares rose 18.28% to $3.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.8 million, marking a year-over-year increase of 18.28%. This contributed to the annual value of $3.8 million for FY2024, which is 18.28% up from last year.
  • According to the latest figures from Q4 2024, Ionis Pharmaceuticals' Treasury Shares is $3.8 million, which was up 18.28% from $3.2 million recorded in Q4 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Treasury Shares peaked at $3.8 million during Q4 2024, and registered a low of $1.5 million during Q1 2020.
  • For the 3-year period, Ionis Pharmaceuticals' Treasury Shares averaged around $3.3 million, with its median value being $3.2 million (2023).
  • Data for Ionis Pharmaceuticals' Treasury Shares shows a peak YoY skyrocketed of 343.74% (in 2020) over the last 5 years.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Treasury Shares stood at $2.4 million in 2020, then grew by 10.28% to $2.6 million in 2021, then grew by 5.65% to $2.8 million in 2022, then rose by 17.10% to $3.2 million in 2023, then rose by 18.28% to $3.8 million in 2024.
  • Its Treasury Shares was $3.8 million in Q4 2024, compared to $3.2 million in Q4 2023 and $2.8 million in Q4 2022.